Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2018, Vol. 45 Issue (2): 166-169    DOI: 10.12891/ceog3018.2018
Original Research Previous articles | Next articles
Follicular fluid anti-Müllerian hormone, inhibin-A, progesterone, and estradiol level differences in patients under controlled ovarian stimulation
M.B. Celtemen1, *(), P. Telli Celtemen1, N. Bozkurt2, C. Karakaya3, S. Elberg4, R.H. Gursoy2
1 Çankiri State Hospital, Department of Obstetrics and Gynecology, Cankiri, Turkey
2 Gazi University, Faculty of Medicine Department of Obstetrics and Gynecology, Ankara, Turkey
3 Gazi University Hospital IVF Center, Ankara, Turkey
4 Gazi University, Faculty of Medicine, Department of Medical Biochemistry, Ankara, Turkey
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: The aim of this study is to determine the differentiation between follicular fluid (FF) anti-Müllerian hormone (AMH), inhibin-A, progesterone (P), and estradiol (E2) levels in patients with poor response, normal response, and high response after controlled ovarian stimulation and the relationship between this differentiation and pregnancy outcome. Materials and Methods: The prospective study included 64 patients who applied for IVF treatment, during a two-month period, in Gazi University Infertility Center. Patients were evaluated in three groups: poor-responders (n=18), normo-responders ( n=26), and high-responders ( n=20), for their controlled ovarian stimulation response. Quantitative measurements of AMH, inhibin-A, P, and E2 were made by ELISA. Results: The FF, AMH, inhibin-A, E2, and P levels were all found to be similar in the groups. The pregnancy rates were 11.0% in the poor-responders, 27.0% in the normo-responders, and 16.7% in the high-responder group. Although higher inhibin-A, AMH, P, and E2 hormones were all detected in the non-pregnant, as compared to the pregnant patients, no statistically significant relationship was found. Conclusion: In this study, inhibin-A, P, E2, and AMH hormone FF levels were not found to be correlated with the ovulation induction response nor effective for predicting the pregnancy outcome.
Key words:  Follicular fluid      AMH      inhibin-A      Progesterone      Estradiol      IVF outcome      Controlled ovarian hyperstimulation     
Published:  10 April 2018     
*Corresponding Author(s):  M.B. CELTEMEN     E-mail:  mbceltemen@gmail.com

Cite this article: 

M.B. Celtemen, P. Telli Celtemen, N. Bozkurt, C. Karakaya, S. Elberg, R.H. Gursoy. Follicular fluid anti-Müllerian hormone, inhibin-A, progesterone, and estradiol level differences in patients under controlled ovarian stimulation. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 166-169.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3018.2018     OR     https://ceog.imrpress.com/EN/Y2018/V45/I2/166

[1] J.H. Check, A. DiAntonio, D.L. Check, M.P. Dougherty, G. Diantonio. A study to determine if estrogen (E) is needed to induce de novo progesterone (P) receptors on gamma/delta t cells as evidenced by determining the degree of rise of progesterone induced blocking factor (PIBF) following P exposure in males[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 419-420.
[2] E. Kadour-Peero, S. Khoury, J. Awad, L. Shpritz, L. Chen-Konak, C. Shechner, L. Saiegh. Determination of estradiol and progesterone concentrations in human scalp hair[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 268-271.
[3] R. Csorba, P. Tsikouras, A. Bothou, S. Zervoudis, G. Iatrakis, X. Anthoulaki, D. Deuteraiou, A. Chalkidou, G. F. von Tempelhoff. Air travel during pregnancy: an update review and practical recommendation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 862-866.
[4] Shun Akaeda, Daiki Kobayashi, Kyoko Shioda, Mikio Momoeda. Relationship between serum progesterone concentrations and pregnancy rates in hormone replacement treatment-frozen embryo transfer using progesterone vaginal tablets[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 695-698.
[5] P. Bakas, M. Simopoulou, P. Panagopoulos, N. Salakos, Ch. Siristatidis. Luteal phase progesterone and estradiol concentrations and their relation to the outcome of IVF/ICSI cycles with controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 727-730.
[6] J.H. Check, J. Liss, D. Check. The beneficial effect of luteal phase support on pregnancy rates in women with unexplained infertility[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 447-449.
[7] Z. Kalem, M.N. Kalem, N. Akgün, A.E. Kaya, B. Bakirarar, S. Aydın. The relationship between the levels of anti-Müllerian hormone, vaspin, visfatin, and the patterns of nutrition and menstruation in non-polycystic ovary syndrome and non-obese young women[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 258-264.
[8] J.H. Check, M.P. Dougherty. Use of sympathomimetic amines to correct premenstrual urticaria and anaphylaxis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 309-312.
[9] J.H. Check. Pros and cons of the use of progesterone to reduce miscarriage rates[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 652-655.
[10] L.E. Prado Correia, B.C. de Almeida, E. Chada Baracat, I. Silva, J.M. Soares Júnior, C.E. Bonduki, M. Abi Haidar. Efficacy and effects of transdermal hormone therapy in postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 735-740.
[11] J.H. Check. Intractable severe peri-ovulatory sneezing abrogated by injection of human chorionic gonadotropin[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 781-781.
[12] E. Djakovic, S. Rakic. Depression, anxiety, and stress after preterm delivery: role of previous progesterone therapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 214-217.
[13] H. Takagi, T. Sasagawa, Y. Osaka. Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 312-315.
[14] J.H. Check, J. Aly. Improving the chance of successful implantation – part 2 – Circumventing immune rejection and the fetal semi-allograft[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 9-13.
[15] T.H. Kim, H.H. Lee, J.M. Kim, A. Lee, J. Park, Y. Kim. A comparison in vitamin D receptor expression during oral menopausal hormone therapy and vaginal estrogen therapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 39-43.
No Suggested Reading articles found!